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Area at Risk by T2w CMR
The Resolution of the Retrospective RadioWave Paradigm?We appreciate the interest and comments from Dr.
Mewton and colleagues about our recently published
work (1). In the context of myocardial infarction (MI),
tissue edema appears initially in the form of car-
diomyocyte swelling during the early stages of
ischemia and is then signiﬁcantly exacerbated on
restoration of blood ﬂow to the ischemic region (2).
The relationship between MI and disturbed cardiac
magnetic resonance (CMR) T2 was initially reported 3
decades ago. However, the potential correlation be-
tween the extent of post-MI altered T2-weighted CMR
imaging and the actual area at risk (AAR) was not
proposed until 2006 (3). After this initial in vivo
report, the extent of post-MI T2 CMR alteration hasbeen exponentially used to quantify the extent of
AAR, assuming its accuracy in this regard. For many
years, the post-MI edematous reaction was assumed to
appear early after ischemia/reperfusion and to persist
in stable form for at least 1 week. Our recent report on
the post-ischemia/-reperfusion bimodal edema phe-
nomenon (1) disrupts this classical view and calls for
revisiting the assumptions described here.
Dr. Mewton and colleagues raise a highly relevant
issue: What are the implications of our ﬁndings for
the retrospective AAR (and myocardial salvage)
quantiﬁcation? Given that myocardial edema ﬂuctu-
ates during the ﬁrst week after MI, it seems intuitive
to argue that CMR-based AAR quantiﬁcation will vary
during the initial days after reperfusion, yet this is to
be formally proven. Our data suggest that the use
of CMR-based surrogate markers of infarct size
(i.e., normalized to AAR) in clinical trials evaluating
the effect of cardioprotective therapies, while inter-
esting to reduce sample size, is a risky business. This
call of warning is not new, and has been previously
proposed by other investigators (including Dr. Mew-
ton and colleagues), and our work supports this pre-
caution. Please note, given the controversy in the
ﬁeld, in our recently published METOCARD-CNIC
(Effect of Metoprolol in Cardioprotection During an
Acute Myocardial Infarction) trial, we intentionally
chose total infarct size as the primary endpoint,
having salvage index as a secondary analysis (4,5).Rodrigo Fernández-Jiménez, MD
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6 Versus 12 Months of
Dual Antiplatelet TherapyWith great interest, I read the article by Colombo et al.
(1) that examined the noninferiority of 6 versus 12
months of dual antiplatelet therapy (DAPT) in
patients undergoing percutaneous coronary inter-
vention with second-generation drug-eluting stents.
The investigators described in the Results section
(p. 2091) that “There was at least 1 occurrence of the
primary composite endpoint by 12 months in 31 pa-
tients in the 6-month DAPT group (4.5%; 95% CI: 2.9
to 6.1) and 27 patients in the 12-month DAPT group
(3.7%; 95% CI: 2.3 to 5.1; p ¼ 0.469) (Table 5). There
was a 0.8% (95% CI: -2.4 to 1.7) difference in occur-
rence of the primary endpoint between the 6-month
and 12-month groups. The upper limit of the 95% CI
was lower than the pre-set margin of 2%, conﬁrming
the noninferiority hypothesis (p < 0.05).” However,
on the basis of the result (31 of 682 vs. 27 of 717) in
Table 5, the 95% conﬁdence interval (CI) for the dif-
ference between 2 sample proportions is -1.3% to
2.9% (90% CI: -1.0 to 2.5). Therefore, the upper limit
of the 95% CI appears more than the pre-set margin of
2%, rejecting the noninferiority hypothesis of 6
months versus 12 months of DAPT. It would be of
great help if the investigators could provide the
method they used to calculate 95% CI.*Hideaki Kaneda, MD, PhD
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Establish NoninferiorityIn presenting the results of the SECURITY (Second-
Generation Drug-Eluting Stent Implantation Fol-
lowed by 6- Versus 12-Month Dual Antiplatelet
Therapy) trial, Colombo et al. (1) concluded that
“6 months of DAPT appeared noninferior to a
12-month regimen with respect to the primary com-
posite endpoint.” However, this conclusion, repeated
several times in the paper, is not supported by the
data.
The composite event was observed in 31 of 682
patients in the 6-month treatment arm, and in 27 of
717 patients in the 12-month arm. The risks were
correctly reported as 4.5% versus 3.7%, and the risk
difference as 0.8%. The 95% conﬁdence interval was
given as -2.4% to 1.7%, such that “the upper limit of
the 95% CI was lower than the pre-set margin of 2%,
conﬁrming the noninferiority hypothesis.” Unfortu-
nately, the conﬁdence bounds are incorrect. The
tell-tale sign of a problem is the asymmetry; the
conﬁdence interval should be approximately sym-
metric about the point estimate of 0.8%. Reanalysis
shows an asymptotic 95% conﬁdence interval of -1.3%
to 2.9%, which exceeds the noninferiority margin. If
an exact conﬁdence interval is preferred, which may
be a good idea given the low numbers of events, the
bounds are -1.7% to 3.9%. This means that the data
are compatible with an absolute excess risk of a
composite event of up to 2.9% (or 3.9%) in a patient
treated for 6 months, compared with a patient treated
for 12 months. Noninferiority up to an excess risk of
2% does not hold.
The problem remains if a 1-sided 95% conﬁdence
interval is obtained, as it should according to the
Methods section. A 1-sided upper limit on the risk
difference of 0.8% is 2.5% (asymptotic method) or
3.4% (exact method). In all instances, the upper limit
exceeds the noninferiority margin.
Another issue that argues against noninferiority is
the rather high proportion of patients (34%) in
the 6-month treatment group who continued their
medications beyond the scheduled stopping time.
Non-compliance with the assigned treatment dilutes
the contrast between the groups. This favors the null
hypothesis and causes a conservative bias in su-
periority trials: indeed, if a signiﬁcant difference is
observed between the treatment arms despite
noncompliance, the true difference must be even
greater. In contrast, in a noninferiority trial, the bias
caused by noncompliance runs against the tested
